Dependence of Castration-Resistant Prostate Cancer (CRPC) Stem Cells on CRPC-Associated Fibroblasts

被引:22
|
作者
Adisetiyo, Helty [1 ,2 ]
Liang, Mengmeng [3 ]
Liao, Chun-Peng [4 ]
Jeong, Joseph H. [5 ]
Cohen, Michael B. [6 ]
Roy-Burman, Pradip [1 ,3 ]
Frenkel, Baruch [1 ,2 ,7 ]
机构
[1] Univ So Calif, Los Angeles, CA 90033 USA
[2] Univ So Calif, Inst Med Genet, Los Angeles, CA 90033 USA
[3] Univ So Calif, Dept Pathol, Los Angeles, CA 90033 USA
[4] Univ So Calif, Keck Sch Med, Ctr Appl Mol Med, Los Angeles, CA 90033 USA
[5] Med Coll Wisconsin, Dept Dermatol, Milwaukee, WI 53226 USA
[6] Univ Utah, Dept Pathol, Salt Lake City, UT USA
[7] Univ So Calif, Dept Orthopaed Surg, Los Angeles, CA 90033 USA
基金
美国国家卫生研究院;
关键词
RB DEFICIENCY; IN-VITRO; TUMORIGENESIS; THERAPY; MODELS; NICHE; P53;
D O I
10.1002/jcp.24546
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
We previously established a role for cancer-associated fibroblasts (CAF) in enhancing the self-renewal and differentiation potentials of putative prostate cancer stem cells (CSC). Our published work focused on androgen-dependent prostate cancer (ADPC) using the conditional Pten deletion mouse model. Employing the same model, we now describe the interaction of CAF and CSC in castration-resistant prostate cancer (CRPC). CAF isolated from ADPC (ADPCAF) and from CRPC (CRPCAF) were compared in terms of their ability to support organoid formation and tumor initiation by CSC from CRPC (CRPCSC) in vitro and in vivo. CRPCSC formed spheroids in vitro and well-differentiated glandular structures under the renal capsules of recipient mice in vivo more effectively in the presence of CRPCAF compared to ADPCAF. Furthermore, whereas CSC with CAF from ADPC formed mostly well-differentiated tumors in our previous study, we now show that CRPCSC, when combined with CRPCAF (but not ADPCAF), can form aggressive, poorly-differentiated tumors. The potential of CRPCAF to support organoid/tumor formation by CRPCSC remained greater even when compared to 10-fold more ADPCAF, suggesting that paracrine factors produced specifically by CRPCAF preferentially potentiate the stemness and tumorigenic properties of the corresponding CSC. This apparently unique property of CRPCAF was notable when the CAF and CSC were grafted in either intact or castrated recipient mice. In both environments, CRPCAF induced in the epithelial compartment higher proliferative activity compared to ADPCAF, indicated by a higher Ki67 index. Factors released by CRPCAF to regulate CRPCSC may be targeted to develop novel therapeutic approaches to manage advanced prostate cancer. J. Cell. Physiol. 229: 1170-1176, 2014. (c) 2014 Wiley Periodicals, Inc.
引用
收藏
页码:1170 / 1176
页数:7
相关论文
共 50 条
  • [21] Cytokines' profiles to predict chemotherapy outcome in castration-resistant prostate cancer (CRPC).
    Mahon, K. L.
    Chatfield, M. D.
    Lee-Ng, M.
    Breit, S. N.
    Brown, D. A.
    Molloy, M. P.
    Marx, G. M.
    Pavlakis, N.
    Boyer, M. J.
    Stockler, M. R.
    Wykes, R.
    Henshall, S. M.
    Sutherland, R. L.
    Horvath, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [22] MLL translocation in two castration-resistant prostate cancer (CRPC) patients.
    Chowdry, Rajasree Pia
    Ledet, Elisa M.
    Phelan, Mary C.
    Sartor, A. Oliver
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [23] Testosterone defining prognosis and predicting response in castration-resistant prostate cancer (CRPC)
    Gomez de Liano, A.
    Reig, O.
    Mellado, B.
    Martin, C.
    Sancho, G.
    Palou, J.
    Anguera, G.
    Arqueros, C.
    Condori, D.
    Maroto-Rey, P.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S702 - S702
  • [24] A resource-based mechanistic framework for castration-resistant prostate cancer (CRPC)
    Vibishan, B.
    Harshavardhan, B. V.
    Dey, Sutirth
    JOURNAL OF THEORETICAL BIOLOGY, 2024, 587
  • [25] Alterations of androgen action in castration-resistant prostate cancer (CRPC) and in abnormalities of virilization
    McPhaul, Michael J.
    Malewska, Alicia
    Vilaythong, Jill
    Glickman, Stephen E.
    Marcelli, Marco
    Sharifi, Nima
    Auchus, Richard J.
    ENDOCRINE JOURNAL, 2010, 57 : S264 - S264
  • [26] Effect of sorafenib on chemotherapy resistance and refractoriness in castration-resistant prostate cancer (CRPC)
    Nabhan, C.
    Tolzien, K.
    Lestingi, T. M.
    Galvez, A.
    Bitran, J. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] Bisphosphonate utilization among men with metastatic castration-resistant prostate cancer (CRPC).
    Morgans, Alicia Katherine
    Graves, Amy J.
    Penson, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Cediranib (AZD2171) in docetaxel-resistant, castration-resistant prostate cancer (CRPC)
    Karakunnel, J. J.
    Gulley, J. L.
    Arlen, P.
    Mulquin, M.
    Wright, J.
    Turkbey, I. B.
    Choyke, P.
    Figg, W. D.
    Dahut, W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Severe zoledronic acid (ZOL)-associated hypophosphatemia and prognosis in patients with castration-resistant prostate cancer (CRPC).
    Warr, Julia
    Yam, David
    VanDraanen, Leah
    Goodall, Shannon
    Giotis, Angie
    Pasetka, Mark
    Isogai, Pierre K.
    Mamedov, Alexandre
    DeAngelis, Carlo
    Emmenegger, Urban
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] CLINICAL STUDY OF MDV3100 IN PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Scher, Howard I.
    Beer, Tomasz
    Higano, Celestia
    Efstathiou, Eleni
    Anand, Aseem
    Hirmand, Mohammad
    Hung, David
    Steve, Larson
    Fleisher, Martin
    Sawyers, Charles
    JOURNAL OF UROLOGY, 2009, 181 (04): : 230 - 230